Latest News on First Trust Value Line 100 ETF (FVL) ETF



  • GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow [April 25 2017 06:09 AM]
  • Analysts expect ~16.5% growth in GlaxoSmithKline’s (GSK) 1Q17 revenues to ~7.3 billion pounds following strong product launches, acquired products from Novartis (NVS), and improvement in the supply chain.... Read more about this First Trust Value Line 100 ETF (FVL) news


  • Vyzulta May Be a Potent Therapy for Glaucoma in the Future [March 27 2017 04:36 AM]
  • Vyzulta growth trends On February 24, 2017, Valeant Pharmaceuticals (VRX) refiled its application with the FDA, seeking regulatory approval for Vyzulta (latanoprostene bunod) as a therapy for open-angle ... Read more about this First Trust Value Line 100 ETF (FVL) news

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center